Insulet (PODD) Revenue Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.01% |
| Dec 31, 2025 | 26.07% |
| Sep 30, 2025 | 24.73% |
| Jun 30, 2025 | 23.46% |
| Mar 31, 2025 | 23.51% |
| Dec 31, 2024 | 23.33% |
| Sep 30, 2024 | 23.14% |
| Jun 30, 2024 | 22.50% |
| Mar 31, 2024 | 22.58% |
| Dec 31, 2023 | 25.32% |
| Sep 30, 2023 | 23.42% |
| Jun 30, 2023 | 26.13% |
| Mar 31, 2023 | 23.71% |
| Dec 31, 2022 | 23.15% |
| Sep 30, 2022 | 22.85% |
| Jun 30, 2022 | 22.23% |
| Mar 31, 2022 | 19.42% |
| Dec 31, 2021 | 25.85% |
| Sep 30, 2021 | 23.77% |
| Jun 30, 2021 | 24.37% |
| Mar 31, 2021 | 25.17% |
| Dec 31, 2020 | 24.04% |
| Sep 30, 2020 | 26.80% |
| Jun 30, 2020 | 30.17% |
| Mar 31, 2020 | 32.68% |
| Dec 31, 2019 | 23.61% |
| Sep 30, 2019 | 20.70% |
| Jun 30, 2019 | 19.72% |
| Mar 31, 2019 | 18.20% |
| Dec 31, 2018 | 19.20% |
| Sep 30, 2018 | 19.85% |
| Jun 30, 2018 | 15.63% |
| Mar 31, 2018 | 16.60% |
| Dec 31, 2017 | 17.68% |
| Sep 30, 2017 | 17.34% |
| Jun 30, 2017 | 16.55% |
| Mar 31, 2017 | 16.33% |
| Dec 31, 2016 | 17.02% |
| Sep 30, 2016 | 16.30% |
| Jun 30, 2016 | 22.08% |
| Mar 31, 2016 | 23.51% |
| Dec 31, 2015 | 24.72% |
| Sep 30, 2015 | 22.91% |
| Jun 30, 2015 | 21.43% |